GFAP and early-onset autosomal dominant Alzheimer disease: Serum GFAP differentiated Alzheimer’s disease patients from control with an area under the curve (AUC) of 0.87 and from behavioural frontotemporal dementia with an AUC of 0.81, highlighting GFAP’s potential as a differential biomarker.